Clinical analysis of recombinant activated factor VIIa for 18 patients with severe bleeding / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 409-411, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-359472
ABSTRACT
<p><b>OBJECTIVE</b>To find a kind of quick and effective haemostasis to decrease the mortality of severe bleeding.</p><p><b>METHODS</b>18 severe bleeding patients with different cause received recombinant activated factor VIIa (rFVIIa) were analyzed retrospectively.</p><p><b>RESULTS</b>Of total 18 cases with severe bleeding, 13 cases cured, 3 cases were effective, 2 cases ineffective. The total clinical effective rate is 88.89%. After using rFVIIa, the PT, APTT and fibrinogen level of 6 DIC patients returned to normal within 12 hours; 13 patients whose the amount of bleeding can be evaluated stopped bleeding quickly. The fastest onset time was 10 min.</p><p><b>CONCLUSION</b>rFVIIa can stanch severe bleeding for a variety of reasons rapidly and effectively, including coagulopathy, thrombocytopenia, and obstetric hemorrhage. Application of rFVIIa may decrease mortality, when conventional treatment is not valid.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Coagulation Disorders
/
Recombinant Proteins
/
Factor VIIa
/
Retrospective Studies
/
Treatment Outcome
/
Therapeutic Uses
/
Drug Therapy
/
Hemorrhage
Type of study:
Observational study
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS